Table 1. Demographic and Clinical Data.

Patient characteristic	Total patients receiving implant (N = 33)
Sex, No. (%)
Female	15 (45.5)
Male	18 (54.5)
Age, mean (SD) [range], y	34.6 (13.5) [18-75]
Duration of epilepsy, mean (SD) [range], y	20.4 (12.4) [3.2-66.2]
Baseline seizure count per 30 d, median (IQR)	12 (2-147)
No. of antiseizure medications taken prior to enrollment, mean (SD) [range]	7.8 (4.3) [3-15]
No. of antiseizure medications at baseline, mean (SD)	3.2 (1.2)
ASM, No. (%)
2	12 (36.4)
3	7 (21.2)
4	11 (33.3)
5	2 (6.1)
6	0 (0.0)
7	1 (3.0)
Prior vagus nerve stimulation, No. (%)	4 (12.1)
Location of seizure onset, No. (%)
Temporal	15 (45.4)
Right	4
Left	11
Frontal	9 (27.3)
Right	4
Left	5
Other	9 (27.3)
Right	4
Left	5
Laterlization of seizure onset, No. (%)
Right	13 (39.4)
Left	20 (60.6)

Abbreviation: ASM, antiseizure medication.